Personal profile

Chaoyun Pan, Ph.D., Professor at the Zhongshan School of Medicine, Sun Yat-sen University. Dr. Pan completed his doctoral studies at Nanjing University in 2016, after which he conducted postdoctoral research at Emory University in the United States from 2016 to 2020. In 2020, he joined Sun Yat-sen University as an Associate Professor in the Department of Biochemistry and Molecular Biology, and he was promoted to Professor in 2025. He has been awarded several grants from National Natural Science Foundation of China (NSFC). He also serves as an Associate Editor for BMC Biology and Scientific Reports.

Dr. Pan’s research focuses on cancer, investigating the mechanisms of systemic and cellular metabolism in tumorigenesis, metastasis, and therapy resistance, as well as their translational implications. His work has been published in high-impact journals, including Cell Metabolism, Journal of Clinical Investigation, and Nature Communications, among others. Furthermore, he has co-authored four national-level textbooks in biochemistry.

Academic achievement

Selected Publications

1.Zheng C, Niu G, Tan H, Huang X, Lu J, Mai Q, Yu T, Zhang C, Chen S, Wei M, Pan W, Guo Y, Wang J, Xu M, Yao S, Liu J, Li J, Pan C. A noncanonical role of SAT1 enables anchorage independence and peritoneal metastasis in ovarian cancer. Nat Commun. 2025;16(1):3174. Epub 2025/04/04. doi: 10.1038/s41467-025-58525-8. PubMed PMID: 40180916; PMCID: PMC11968987.

2.Zheng C, Tan H, Niu G, Huang X, Lu J, Chen S, Li H, Zhu J, Zhou Z, Xu M, Pan C, Liu J, Li J. ACAT1-Mediated ME2 Acetylation Drives Chemoresistance in Ovarian Cancer by Linking Glutaminolysis to Lactate Production. Adv Sci (Weinh). 2025:e2416467. Epub 2025/02/14. doi: 10.1002/advs.202416467. PubMed PMID: 39951294.

3.Li J, Zheng C, Mai Q, Huang X, Pan W, Lu J, Chen Z, Zhang S, Zhang C, Huang H, Chen Y, Guo H, Wu Z, Deng C, Jiang Y, Li B, Liu J, Yao S, Pan C. Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer. Cell Metab. 2023;35(11):2044-59 e8. Epub 2023/10/28. doi: 10.1016/j.cmet.2023.10.002. PubMed PMID: 37890478.

4.Li J, Lu J, Xu M, Yang S, Yu T, Zheng C, Huang X, Pan Y, Chen Y, Long J, Zhang C, Huang H, Dai Q, Li B, Wang W, Yao S, Pan C. ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models. J Clin Invest. 2023;133(2). Epub 2022/11/16. doi: 10.1172/JCI161544. PubMed PMID: 36378528; PMCID: PMC9843051.

5.Boese AC, Kang J, Hwang JS, Kim J, Eun K, Malin CM, Magliocca KR, Pan C, Jin L, Kang S. Succinyl-CoA ligase ADP-forming subunit beta promotes stress granule assembly to regulate redox and drive cancer metastasis. Proc Natl Acad Sci U S A. 2023;120(23):e2217332120. Epub 2023/05/30. doi: 10.1073/pnas.2217332120. PubMed PMID: 37253003; PMCID: PMC10266061.

6.Liu Z, You Y, Chen Q, Li G, Pan W, Yang Q, Dong J, Wu Y, Bei JX, Pan C, Li F, Li B. Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis. Mol Ther. 2022;30(2):606-20. Epub 2021/10/04. doi: 10.1016/j.ymthe.2021.07.015. PubMed PMID: 34601133; PMCID: PMC8821954.

7.Li J, Zheng C, Wang M, Umano AD, Dai Q, Zhang C, Huang H, Yang Q, Yang X, Lu J, Pan W, Li B, Yao S, Pan C. ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer. Oncogene. 2022;41(8):1114-28. Epub 2022/01/19. doi: 10.1038/s41388-021-02149-x. PubMed PMID: 35039634.

8.Pan C, Li B, Simon MC. Moonlighting functions of metabolic enzymes and metabolites in cancer. Mol Cell. 2021;81(18):3760-74. Epub 2021/09/22. doi: 10.1016/j.molcel.2021.08.031. PubMed PMID: 34547237.

9.Pan C, Kang J, Hwang JS, Li J, Boese AC, Wang X, Yang L, Boggon TJ, Chen GZ, Saba NF, Shin DM, Magliocca KR, Jin L, Kang S. Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1. Nat Commun. 2021;12(1):4960. Epub 2021/08/18. doi: 10.1038/s41467-021-24845-8. PubMed PMID: 34400618; PMCID: PMC8368102 platinum-based chemotherapy" technology. The other authors declare no competing interests.

10.Li J, Pan C, Boese AC, Kang J, Umano AD, Magliocca KR, Yang W, Zhang Y, Lonial S, Jin L, Kang S. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling. Clin Cancer Res. 2020;26(14):3843-55. Epub 2020/04/29. doi: 10.1158/1078-0432.CCR-19-3790. PubMed PMID: 32341033; PMCID: PMC7367757.

11.Pan C, Jin L, Wang X, Li Y, Chun J, Boese AC, Li D, Kang HB, Zhang G, Zhou L, Chen GZ, Saba NF, Shin DM, Magliocca KR, Owonikoko TK, Mao H, Lonial S, Kang S. Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. J Clin Invest. 2019;129(6):2431-45. Epub 2019/05/14. doi: 10.1172/JCI124550. PubMed PMID: 31081803; PMCID: PMC6546469.

12.Pan C, Chun J, Li D, Boese AC, Li J, Kang J, Umano A, Jiang Y, Song L, Magliocca KR, Chen ZG, Saba NF, Shin DM, Owonikoko TK, Lonial S, Jin L, Kang S. Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. J Clin Invest. 2019;129(10):4110-23. Epub 2019/08/27. doi: 10.1172/JCI125963. PubMed PMID: 31449053; PMCID: PMC6763259.